Novavax (NVAX) Free Cash Flow (QoQ) (2010 - 2026)
Novavax (NVAX) Free Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Novavax | 1.23 Bn | 440.77 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.82% |
| Dec 31, 2025 | -141.07% |
| Sep 30, 2025 | 185.62% |
| Jun 30, 2025 | 31.92% |
| Mar 31, 2025 | -8.39% |
| Dec 31, 2024 | -18.40% |
| Sep 30, 2024 | -146.31% |
| Jun 30, 2024 | 471.45% |
| Mar 31, 2024 | 39.35% |
| Dec 31, 2023 | -74.63% |
| Sep 30, 2023 | 53.67% |
| Jun 30, 2023 | 47.55% |
| Mar 31, 2023 | -491.17% |
| Dec 31, 2022 | 46.81% |
| Sep 30, 2022 | 32.02% |
| Jun 30, 2022 | -46.27% |
| Mar 31, 2022 | 65.38% |
| Dec 31, 2021 | -97.15% |
| Sep 30, 2021 | -223.91% |
| Jun 30, 2021 | -80.96% |